Experienced in Midline Lethal Granuloma

Dr. Zanetta S. Lamar

Oncology | Hematology | Transplant Surgery
Florida Oncology & Hematology
708 Goodlette-Frank Rd, Suite 200, 
Naples, FL 
Accepting New Patients
Offers Telehealth
14 Years of Experience
Experienced in Midline Lethal Granuloma
Florida Oncology & Hematology
708 Goodlette-Frank Rd, Suite 200, 
Naples, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zanetta Lamar is an Oncologist and a Hematologist in Naples, Florida. Dr. Lamar has been practicing medicine for over 14 years and is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. Her top areas of expertise are Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Splenic Neoplasm, and Bone Marrow Transplant. Dr. Lamar is currently accepting new patients.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Transplant Surgery
Licenses
Internal Medicine in FL
Hospital Affiliations
Naples Community Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Florida Oncology & Hematology
708 Goodlette-Frank Rd, Suite 200, Naples, FL 34102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy
A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 20, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Study Phase: Phase 2
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drugs: 6, 8-Bis(Benzylthio)octanoic Acid, Bendamustine
Study Phase: Phase 1
View 3 Less Clinical Trials

21 Total Publications

Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study.
Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study.
Journal: JMIR cancer
Published: April 09, 2020
Similar Doctors
Experienced in Midline Lethal Granuloma
Dr. Gustavo Westin
Hematology | Oncology
Experienced in Midline Lethal Granuloma
Dr. Gustavo Westin
Hematology | Oncology

Florida Cancer Specialists And Research Institute, LLC

8260 Gladiolus Dr, 
Fort Myers, FL 
 (25.9 miles away)
239-437-5755
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gustavo Westin is a Hematologist and an Oncologist in Fort Myers, Florida. Dr. Westin is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Familial Colorectal Cancer, Lung Cancer, Colorectal Cancer, and Lynch Syndrome.

Experienced in Midline Lethal Granuloma
Dr. Santosh Kagathur
Hematology Oncology | Oncology | Hospital Medicine
Experienced in Midline Lethal Granuloma
Dr. Santosh Kagathur
Hematology Oncology | Oncology | Hospital Medicine

Lee Health System Inc

3501 Health Ctr Blvd, Suite 1119, 
Estero, FL 
 (16.5 miles away)
239-468-0226
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Santosh Kagathur is a Hematologist Oncology specialist and an Oncologist in Estero, Florida. Dr. Kagathur is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Midline Lethal Granuloma, Burkitt Lymphoma, and Angiosarcoma. Dr. Kagathur is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lamar's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile